CNA FINANCIAL ANNOUNCES THIRD QUARTER 2026 NET INCOME OF $0.72 PER SHARE AND CORE INCOME OF $0.75 PER SHARE

CNA Financial reported Q3 2026 net income of $196 million, down from $403 million a year earlier, while core income fell to $203 million from $409 million. P&C core income declined to $397 million as the combined ratio worsened to 97.0% from 92.8%, and Life & Group recorded a $171 million core loss, including a $137 million after-tax impact from annual long-term-care reserve assumption updates; management said portfolio actions are expected to almost entirely offset the updates economically over time. Net written premiums grew 3%, and the board declared a quarterly dividend of $0.48 per share.

Analysis

The key concern is not the headline earnings decline but that underlying P&C loss-cost pressure is broad and already persisted through the first half. Pricing is not yet clearly outrunning claims inflation: renewal rate gains are modest, while exposure growth and retention can preserve premium volume without restoring underwriting margin. That makes CNA’s selective-capacity stance economically sensible, but risks slower growth if competitors keep writing business at softer terms.

Reported segment results obscure the split: Commercial’s near-break-even all-in underwriting includes catastrophe and reserve noise, while International’s strong reported result relies on unusually favorable prior-year development despite weaker underlying performance. Do not extrapolate the International headline. Specialty also faces higher acquisition costs, a warning that premium growth may be expensive to buy.

The LTC reserve narrative is a valuation-quality issue. Management’s claimed economic offset from portfolio actions is not yet earnings; duration extension may improve future investment income but does not eliminate uncertainty in care-cost and morbidity assumptions or the timing mismatch under GAAP. Higher rates also pressure AOCI/book value, so the stock has competing rate sensitivities: better reinvestment income versus weaker reported equity.

Near term, the release supports caution rather than a high-conviction directional bet absent the share-price reaction and valuation context. Over 1–3 months, focus on management’s quantified LTC cash-flow sensitivity and whether pricing actions keep pace with loss trends. Over 6–18 months, sustained underlying ratio deterioration would imply lower normalized underwriting returns and constrain multiple support. The contrarian risk to a bearish read is that current reserve expense is largely non-cash/accounting timing and reinvestment yields gradually show up in income.

Key Decisions for Investors

• Keep CNA underweight versus a diversified P&C peer exposure; avoid adding to a short solely on the earnings print. Reassess after the call and share-price reaction, since valuation and expectations are not supplied here.
• Set a 1–3 month alert for a quantified LTC reserve/cash-flow bridge and updated cost-of-care and morbidity sensitivities. Treat the claimed investment-income offset as unverified until realized in segment earnings and cash flows.
• Track underlying combined and loss ratios, not headline combined ratios: a sustained move back toward prior-year underlying performance would weaken the bearish thesis; further deterioration or rate increases failing to exceed loss-cost trends would strengthen it.
• Watch fixed-income reinvestment income against AOCI/book-value effects over the next 6–18 months. Better recurring investment income without renewed reserve strengthening is the key upside falsifier; additional adverse LTC assumptions or persistently weaker underlying underwriting would argue for continued underweight.